Detection of acute rejection is based on the identification of infiltration and cellular damage in myocardial biopsies sequentially performed after heart transplantation. Grading of rejection uses the criteria of the International Society of Heart and Lung Transplantation (ISHLT) classification. This provides a consensus framework for reporting results and for treatment of acute rejection based on histological findings. This type of widespread patient management is associated with good long-term results.
The invasive nature, discomfort to the patient, and cost of repeat biopsies have led to a search for new diagnostic tests, to provide alternative diagnostic methods for rejection. In the current issue, Abdallah et al. used both plasma tumour necrosis factor-alpha and interleukin-6. These two products of macrophage activation were used to evaluate the presence of rejection. They induced proliferation and activation of T-and B-lymphocytes and eventually exerted a deleterious effect on the graft'
11
. Endomyocardial biopsy was used as a reference method with which to compare cytokine levels. Results showed increased plasma cytokines during the first few weeks after heart transplantation and a slow reduction of serum levels thereafter. Several patients with moderate or severe rejection showed high levels of tumour necrosis factor-alpha and interleukin-6 up to one year from the operation. Higher plasma cytokine concentrations were found in patients showing cellular damage at biopsy compared with those in whom no such damage was detected'
. The authors rightly suggest that these products of macrophage activation could prove useful as markers for rejection.
This and other attempts to compare a new non-invasive method for the detection of rejection with endomyocardial biopsies face a crucial objection: the sensitivity of endomyocardial biopsy; in other words, how 'gold' is the standard used as a reference for acute rejection against which other methods are compared. The histological expression of allograft rejection is patchy, and in explants of patients who die as a result of refractory rejection, foci of rejection are often surrounded by large areas of apparently intact myocardial tissue' 21 . Therefore, endomyocardial biopsies of rejecting hearts may lead to sampling error. In acute myocarditis, where myocardial round-cell infiltration and damage are histologically indistinguishable from rejection, the estimated sensitivity of endomyocardial biopsy, as shown in in vivo and ex vivo studies, ranges from 0-25%. In cardiac rejection, no such studies have been performed, rendering the sensitivity of biopsy a speculative issue.
In previous studies'
, detection of myocardial damage through myocardial uptake of In 111-labelled monoclonal antimyosin antibodies was deemed to constitute a test of higher sensitivity than endomyocardial biopsy for the detection of rejection'
51
. Sequential use of these diagnostic antibodies after transplantation yields individual time-activity curves of rejection, information not available from any other form of human solid organ transplantation. Analysis of these curves shows the impressive variability of the phenomenon of rejection and gives some fascinating insights into this natural history in cyclosporine-treated patients. The main findings drawn from antimyosin studies are' : (a) the consideration of rejection as a continuous rather than an erratic or episodic phenomenon; therefore, the term widely used of 'rejection episodes' probably does not reflect the true nature of rejection; (b) the possibility of persistence of low-grade rejection years after transplantation in the absence of functional ventricular deterioration, and (c) the detection of a state of immunological tolerance to the graft in some patients and the great inter-individual variability of this phenomenon, both in terms of its occurrence and timing after transplantation.
The clinical implications are several. Firstly, a normal biopsy does not rule out rejection. On the other hand, after treatment of 'rejection episodes' a normal biopsy does not imply that rejection has disappeared. It might be that because rejection is less conspicuous, the sampling error is greater; this may be particularly important when assessing certain old and new anti-rejection drugs. Secondly, patients should probably be screened throughout life for 0195-668X/97/060885+11 $18.00/0 1997 The European Society of Cardiology rejection; thirdly, treatment for rejection must be tailored to each patient. The above considerations emphasize the importance of having a sensitive non-invasive diagnostic test for rejection -both for risk stratification and treatment -to provide a rationale for patient management. On the other hand, the precise clinical significance of 'false positive' results in the new tests for detecting rejection in relation to results of biopsies should be ascertained before such tests are definitely abandoned as 'non-specific'. In the paper by Abdallah AN et a/. [1] high serum tumour necrosis factor-alpha and interleukin-6 levels detected long-term after transplantation possibly indicate ongoing rejection.
New diagnostic developments for rejection should focus on the significance of normal and abnormal markers for rejection in relation to the biopsies, but also on its evolving patterns after transplantation. This could eventually lead to design algorithms for elective non-invasive patient management. However, the lack of specificity of many non-invasive tests for detecting rejection, particularly in the early months after transplantation (i.e. effects of myocardial preservation, extracorporeal circulation or infection), provide a solid argument for not abandoning biopsies during this period.
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